| Generation of a dual-function multi-engager antibody for simultaneous targeting NK cells and tumor cells
|
| 11:00 AM EDT | May 22, 2025
|
REGISTER NOW
|
|
|
The relentless pursuit of innovative cancer immunotherapies has unveiled natural killer (NK) cells as formidable agents in the fight against malignancies. While these innate immune cells possess inherent tumor-killing capabilities, their full potential remains constrained by regulatory mechanisms and tumor evasion strategies. At the forefront of this research stands ADAM17, a membrane-associated protease that functions as both a negative regulatory checkpoint in NK cells and a tumor-associated antigen overexpressed in various malignancies. Creative Biolabs is honored to invite Dr. Bruce Walcheck to introduce the Targeted ADAM17 Blocker and Killer (TABK), an ingenious multi-engager antibody complex that simultaneously enhances NK cell proliferation while directing these empowered immune cells to engage and eliminate ADAM17-expressing tumor cells. Join us to explore how this innovative approach leverages ADAM17's unique dual role to create a potent immunotherapeutic strategy with promising implications for cancer treatment.
|
| This webinar will discuss the following key points:
|
| • ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen
|
| • Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)
|
| • TABK blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation
|
| • TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing
|
 Speaker
|
 |
Bruce Walcheck
Professor at the University of Minnesota
|
|
|
Dr. Bruce Walcheck is a Professor of Immunology at the University of Minnesota. He has been continuously funded by the NIH for over 20 years. His current research focuses on increasing the anti-tumor function of NK cells. The membrane-associated metalloprotease ADAM17 functions, in part, as a negative regulatory checkpoint in NK cells and exhibits overexpression in various malignancies, including ovarian cancer. Dr. Walcheck's group has generated a unique multi-engager complex that selectively blocks ADAM17 in NK cells and simultaneously targets these cells to ADAM17 in tumor cells, resulting in enhanced NK cell activation, proliferation, and tumor cell killing.
|
|
REGISTER NOW
Don't miss this opportunity to learn about the latest advances in NK cell therapy and multi-engager antibody technology from one of the field's leading innovators. All attendees who join the live webinar session will receive an official certificate of participation. Please feel free to arrange a call if you have any questions.
|
Meet Us at the Upcoming Events May 7, 2025 | 23rd BioPharma Drug Discovery Nexus Conference
September 2025 | World Bispecific Summit
October 2025 | Exosome-Based Therapeutic Development Summit
November 2025 | World ADC San Diego
December 2025 | Antibody Engineering & Therapeutics (US) 2025
|
|
BOOK A MEETING
Hover over our event page and check out the sweet spots where you can catch up with the Creative Biolabs team!
|
|
Creative biolabs specializes in antibody engineering and recombinant expression with mammalian cells (HEK293 or CHO) at our ISO-certified manufacturing facility. With our advanced hybridoma development and phage display platforms, we are well-positioned to provide our customers with quality rAb products and a broad service portfolio at competitive prices.
|
|
